TriangleNCT02299089 · OUTCOME
CAM2029 Effect on Insulin-like Growth Factor (IGF-1) (Acromegaly)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Day 84
What was measured
Data is presented as number of patients * Within the reference limits (see below) * Above ULN (Upper Limits of Normal) In the Acromegaly group both males and females were included the age was between 42-70 years. The IGF normal range for the different genders and age are presented below. REFERENCE VALUES Males (NMOL/L) 8.34-27.44 (41-45 years) 7.7-26.36 (46-50 years) 7.3-26.34 (51-55 years) 6.64-25.44 (56-60 years) 6.17-25.02 (61-65 years) 5.96-25.48 (66-70 years) Females (NMOL/L) 8.06-26.89 (41-45 years) 7.39-25.44 (46-50 years) 6.92-24.98 (51-55 years) 5.92-22.7 (56-60 years) 5.42-21.96 (61-65 years) 5.07-21.97 (66-70 years)
Analysis population: Pharmacokinetic population (5 acromegaly subjects total)
Groups in this outcome
CAM2029 10 mg q2w (Acromegaly)
CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot
CAM2029 20 mg q4w (Acromegaly)
CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot
| Group | Source count |
|---|---|
| CAM2029 10 mg q2w (Acromegaly) | 3 |
| CAM2029 20 mg q4w (Acromegaly) | 2 |
Reported measurements
Within Normal Limits
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CAM2029 10 mg q2w (Acromegaly) | 2 | Not reported | Not reported | Not reported | Not reported |
| CAM2029 20 mg q4w (Acromegaly) | 1 | Not reported | Not reported | Not reported | Not reported |
Above ULN
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CAM2029 10 mg q2w (Acromegaly) | 1 | Not reported | Not reported | Not reported | Not reported |
| CAM2029 20 mg q4w (Acromegaly) | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- title
- Within Normal Limits
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- title
- Above ULN
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 2
- units
- Participants
- description
- Data is presented as number of patients * Within the reference limits (see below) * Above ULN (Upper Limits of Normal) In the Acromegaly group both males and females were included the age was between 42-70 years. The IGF normal range for the different genders and age are presented below. REFERENCE VALUES Males (NMOL/L) 8.34-27.44 (41-45 years) 7.7-26.36 (46-50 years) 7.3-26.34 (51-55 years) 6.64-25.44 (56-60 years) 6.17-25.02 (61-65 years) 5.96-25.48 (66-70 years) Females (NMOL/L) 8.06-26.89 (41-45 years) 7.39-25.44 (46-50 years) 6.92-24.98 (51-55 years) 5.92-22.7 (56-60 years) 5.42-21.96 (61-65 years) 5.07-21.97 (66-70 years)
- groups
- description
- CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot
- id
- OG000
- title
- CAM2029 10 mg q2w (Acromegaly)
- description
- CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot
- id
- OG001
- title
- CAM2029 20 mg q4w (Acromegaly)
- param Type
- NUMBER
- population Description
- Pharmacokinetic population (5 acromegaly subjects total)
- reporting Status
- POSTED
- time Frame
- Day 84
- title
- CAM2029 Effect on Insulin-like Growth Factor (IGF-1) (Acromegaly)
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice